Early prediction of severe retinopathy of prematurity in infants born at < 32 weeks’ gestation: a multicenter prediction model study
Year: 2026
Type: article
Study design: Observational Study
Abstract: Severe retinopathy of prematurity (ROP) is a vision-threatening condition among infants born at < 32 weeks’ gestation. We aimed to develop and internally validate an early prediction model for severe ROP using routinely available clinical variables. This prospective multicenter cohort study included infants born at < 32 weeks’ gestation admitted to 28 hospitals in Shenzhen, China, between January 2022 and December 2023. The prediction target was the conditional risk of severe ROP among infants surviving to ROP assessment. Severe ROP was defined as stage 3 or higher according to the International Classification of Retinopathy of Prematurity, Third Edition. Candidate predictors were maternal, perinatal, and early neonatal variables available at birth or within the first 24 h. A ridge logistic regression model was developed. Performance was assessed using discrimination, calibration, Brier score, decision curve analysis, bootstrap optimism correction, and leave-one-center-out internal-external validation. Among 1,453 initially identified infants, 112 died before ROP assessment and 5 duplicate records were excluded, leaving 1,336 infants for prediction modeling. Severe ROP occurred in 179 infants (13.4%). The apparent area under the receiver operating characteristic curve (AUC) was 0.844 (95% confidence interval [CI], 0.812–0.876). After 500 bootstrap resamples, the optimism-corrected AUC was 0.831, with an optimism-corrected Brier score of 0.089 and calibration slope of 1.192. In leave-one-center-out internal-external validation, the pooled AUC was 0.789 (95% CI, 0.749–0.827), with a Brier score of 0.094 and calibration slope of 1.031. The model provides investigational early risk stratification among infants surviving to ROP assessment. It must complement, not replace, guideline-recommended ROP screening. Independent external validation and prospective clinical-impact evaluation are required before clinical implementation. Trial registration: Chinese Clinical Trial Registry, ChiCTR2400090262; registered on September 26, 2024, after study commencement (retrospectively registered).
Source: BMC Pediatrics
Language: English
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,090
Award: G9001400198
OpenAlex ID: W7237235341
